Nafenopin
Names | |
---|---|
IUPAC name 2-Methyl-2-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]propanoic acid | |
Other names Nafenoic acid | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
KEGG |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C20H22O3 |
Molar mass | 310.393 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references |
Chemical compound
Nafenopin is a hypolipidemic agent.[1]
References
- ^ Levine, W.G.; Meijer, D.K.F. (1977), "THE CHOLERETIC EFFECT OF NAFENOPIN", Abstracts, Elsevier, p. 395, retrieved 2022-12-21
- v
- t
- e
Lipid-lowering agents (C10)
Cholesterol absorption inhibitors, NPC1L1 | |
---|---|
Bile acid sequestrants/resins (LDL) |
Statins (HMG-CoA reductase, LDL) | |
---|---|
Niacin and derivatives (HDL and LDL) | |
MTTP inhibitors (VLDL) | |
ATP citrate lyase inhibitors (LDL) | |
Thyromimetics (VLDL) |
PPAR agonists (LDL) |
| ||||
---|---|---|---|---|---|
CETP inhibitors (HDL) | |||||
PCSK9 inhibitors (LDL) | |||||
ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III